Clinical Laboratory Improvement Advisory Committee, 2530-2531 [E7-720]

Download as PDF 2530 Federal Register / Vol. 72, No. 12 / Friday, January 19, 2007 / Notices and 7,500 ineligible screened persons during a 3-year period. Data collection will rotate such that interviews will be conducted among one group per year: MSM in year 1, IDU in year 2, and HET in year 3. The type of data collected for each group will vary slightly due to different sampling methods and risk characteristics of the group. Participation of respondents is voluntary and there is no cost to the respondents other than their time. ESTIMATED ANNUALIZED BURDEN HOURS MSM: Screener only ........................................................................................... Screener, survey, and testing .................................................................. IDU: Screener only ........................................................................................... Screener, survey, and testing .................................................................. HET: Screener only ........................................................................................... Screener, survey, and testing .................................................................. Total ................................................................................................... Dated: January 12, 2007. Deborah Holtzman, Reports Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. E7–705 Filed 1–18–07; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Breast and Cervical Cancer Early Detection and Control Advisory Committee sroberts on PROD1PC70 with NOTICES In accordance with section 10(a)(2)of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned committee meeting: Times and Dates: 8:30 a.m.–5 p.m., February 6, 2007; 8:30 a.m.–3 p.m., February 7, 2007. Place: Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Tom Harkin Global Community Center, Building 19, Atlanta, Georgia 30333, Telephone: 404– 639–1717. Status: Open to the public, limited only by the space available. Purpose: The committee is charged with advising the Secretary, Department of Health and Human Services, and the Director, CDC, regarding the early detection and control of breast and cervical cancer. The committee makes recommendations regarding national program goals and objectives; implementation strategies; and program priorities including surveillance, epidemiologic investigations, education and training, information dissemination, professional interactions and collaborations, and policy. VerDate Aug<31>2005 18:10 Jan 18, 2007 Jkt 211001 Number of responses per respondent Number of respondents Respondents 1 1 5/60 65/60 417 13,542 1,250 12,500 1 1 5/60 90/60 104 18,750 1,250 12,500 1 1 5/60 75/60 104 15,625 ........................ ........................ ........................ 48,542 Dated: January 12, 2007. Edward Schultz, Acting Director, Management Analysis and Services Office, Center for Disease Control and Prevention. [FR Doc. E7–721 Filed 1–18–07; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Clinical Laboratory Improvement Advisory Committee In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting. Name: Clinical Laboratory Improvement Advisory Committee (CLIAC). Web site: Frm 00041 Fmt 4703 Total burden (in hours) 5,000 12,500 Matters to be Discussed: The agenda will include a review and discussion of the National Breast and Cervical Cancer Early Detection Program components; and discussion and review of related policies and emerging issues. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Debra Younginer, Executive Secretary, BCCEDCAC, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop K–57, Chamblee, Georgia 30316, Telephone: 770– 488–1074. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both CDC and NCEH/ATSDR. PO 00000 Average burden per response (in hours) Sfmt 4703 https://www.phppo.cdc.gov/CLIAC/ default.aspx. Times and Dates: 8:30 a.m.–5 p.m., February 14, 2007; 8:30 a.m.–3 p.m., February 15, 2007. Place: Omni Hotel at CNN Center, 100 CNN Center, Atlanta, Georgia 30303; Phone: (404) 659–0000, Fax: (404) 525–5050 (https:// www.omnihotels.com/FindAHotel/ AtlantaCNNCenter.aspx). Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people. Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated, the impact on medical and laboratory practice of proposed revisions to the standards, and the modification of the standards to accommodate technological advances. Matters to be Discussed: The agenda will include updates from the CDC, the Centers for Medicare & Medicaid Services, and the Food and Drug Administration; discussion of the status of the ‘‘Notice of Proposed Rulemaking’’ for genetic testing; presentations and discussion concerning the future of health laboratory practice specifically focusing on simple testing in diverse sites; reports and discussions addressing the impact of the Morbidity and Mortality Weekly Report (MMWR) Publication of ‘‘Good Laboratory Practices for Waived Testing Sites’’; a report from the CLIAC Workgroup on ‘‘The Impact of Rapid and Molecular Tests for Infectious Disease Agents on Public Health’’ and discussion of the workgroup’s proposals related to such; and presentations and discussion concerning rapid HIV testing. Agenda items are subject to change as priorities dictate. Providing Oral or Written Comments: It is the policy of CLIAC to accept written public comments and provide a brief period for oral public comments whenever possible. E:\FR\FM\19JAN1.SGM 19JAN1 Federal Register / Vol. 72, No. 12 / Friday, January 19, 2007 / Notices Oral Comments: In general, each individual or group requesting to make an oral presentation will be limited to a total time of five minutes (unless otherwise indicated). Speakers must also submit their comments in writing for inclusion in the meeting’s summary report. To assure adequate time is scheduled for public comments, individuals or groups planning to make an oral presentation should, when possible, notify the contact person below at least one week prior to the meeting date. Written Comments: For individuals or groups unable to attend the meeting, CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, the comments should be received at least one week prior to the meeting date so that the comments may be made available to the committee for their consideration and public distribution. Written comments, one hard copy with original signature, should be provided to the contact person below. Written comments will be included in the meeting’s summary report. Contact Person for Additional Information: Devery Howerton, Acting Chief, Laboratory Practice Standards Branch, Division Public Health Partnerships—Laboratory Systems, National Center for Health Marketing, Coordinating Center for Health Information and Service, CDC, 1600 Clifton Road, NE., Mailstop G–23, Atlanta, Georgia 30333; telephone (404) 718–1016; fax (404) 718– 1080; or via e-mail at DHowerton@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for CDC and the Agency for Toxic Substances and Disease Registry. Dated: January 12, 2007. Edward Schultz, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E7–720 Filed 1–18–07; 8:45 am] Time and Date: 10 a.m.–12 p.m. Eastern Standard Time, February 6, 2007. Place: The teleconference will originate at NCEH/ATSDR in Atlanta, Georgia. To participate, dial 877/315–6535 and enter conference code 383520. Purpose: Under the charge of the BSC, NCEH/ATSDR, the PPRS will provide the BSC, NCEH/ATSDR with advice and recommendations on NCEH/ATSDR program peer review. They will serve the function of organizing, facilitating, and providing a longterm perspective to the conduct of NCEH/ ATSDR program peer review. Matters To Be Discussed: A discussion of Preparedness and Emergency Response Peer Review: (1) Breadth and approach of the review, (2) areas of expertise required for the review, and (3) nominations for a PPRS panel member, a chairperson, peer reviewers, partners and customers; a report on the Site Specific Activities Peer Review; and approval of the revised Peer Reviewer Conflict-ofInterest Form. Agenda items are subject to change as priorities dictate. Supplementary Information: This meeting is scheduled to begin at 10 a.m. Eastern Standard Time. To participate, please dial 877/315–6535 and enter conference code 383520. Public comment period is scheduled for 11 a.m.–11:10 a.m. For Further Information Contact: Sandra Malcom, Committee Management Specialist, Office of Science, NCEH/ATSDR, MS E–28, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone 404/498–0622. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both CDC and NCEH/ATSDR. Dated: January 12, 2007. Edward Schultz, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E7–707 Filed 1–18–07; 8:45 am] BILLING CODE 4163–18–P BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention sroberts on PROD1PC70 with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; The Program Peer Review Subcommittee of the Board of Scientific Counselors (BSC), Centers for Disease Control and Prevention (CDC), National Center for Environmental Health/Agency for Toxic Substances and Disease Registry (NCEH/ATSDR): Teleconference [Document Identifier: CMS–2786] In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), CDC, NCEH/ATSDR announces the aforementioned subcommittee meeting: VerDate Aug<31>2005 18:10 Jan 18, 2007 Jkt 211001 Agency Information Collection Activities: Submission for OMB Review; Comment Request Centers for Medicare & Medicaid Services, HHS. In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. AGENCY: PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 2531 Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the Agency’s function; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. 1. Type of Information Collection Request: Extension of a currently approved collection; Title of Information Collection: Fire Safety Survey Report Forms and Supporting Regulations in 42 CFR 416.44, 418.100, 482.41, 483.70, and 483.470; Use: These forms are used by the State Agencies to record data collected to determine compliance with individual conditions during fire safety surveys and report it to the Federal Government. Form Number: CMS–2786 M, R, S, T, U, V, W, X, Y (OMB#: 0938–0242); Frequency: Reporting—Annually; Affected Public: State, Local or Tribal Government; Number of Respondents: 27,900; Total Annual Responses: 27,900; Total Annual Hours: 2,325. To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS Web site address at https://www.cms.hhs.gov/ PaperworkReductionActof1995, or e-mail your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@cms.hhs.gov, or call the Reports Clearance Office on (410) 786– 1326. Written comments and recommendations for the proposed information collections must be mailed or faxed within 30 days of this notice directly to the OMB desk officer: OMB Human Resources and Housing Branch, Attention: Carolyn Lovett, New Executive Office Building, Room 10235, Washington, DC 20503, Fax Number: (202) 395–6974. Dated: January 10, 2007. Michelle Shortt, Director, Regulations Development Group, Office of Strategic Operations and Regulatory Affairs. [FR Doc. 07–154 Filed 1–18–07; 8:45 am] BILLING CODE 4120–01–P E:\FR\FM\19JAN1.SGM 19JAN1

Agencies

[Federal Register Volume 72, Number 12 (Friday, January 19, 2007)]
[Notices]
[Pages 2530-2531]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-720]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Clinical Laboratory Improvement Advisory Committee

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting.

    Name: Clinical Laboratory Improvement Advisory Committee 
(CLIAC). Web site: https://www.phppo.cdc.gov/CLIAC/default.aspx.
    Times and Dates: 8:30 a.m.-5 p.m., February 14, 2007; 8:30 a.m.-
3 p.m., February 15, 2007.

    Place: Omni Hotel at CNN Center, 100 CNN Center, Atlanta, 
Georgia 30303; Phone: (404) 659-0000, Fax: (404) 525-5050 (https://
www.omnihotels.com/FindAHotel/AtlantaCNNCenter.aspx).
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the 
standards under which clinical laboratories are regulated, the 
impact on medical and laboratory practice of proposed revisions to 
the standards, and the modification of the standards to accommodate 
technological advances.
    Matters to be Discussed: The agenda will include updates from 
the CDC, the Centers for Medicare & Medicaid Services, and the Food 
and Drug Administration; discussion of the status of the ``Notice of 
Proposed Rulemaking'' for genetic testing; presentations and 
discussion concerning the future of health laboratory practice 
specifically focusing on simple testing in diverse sites; reports 
and discussions addressing the impact of the Morbidity and Mortality 
Weekly Report (MMWR) Publication of ``Good Laboratory Practices for 
Waived Testing Sites''; a report from the CLIAC Workgroup on ``The 
Impact of Rapid and Molecular Tests for Infectious Disease Agents on 
Public Health'' and discussion of the workgroup's proposals related 
to such; and presentations and discussion concerning rapid HIV 
testing. Agenda items are subject to change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible.

[[Page 2531]]

    Oral Comments: In general, each individual or group requesting 
to make an oral presentation will be limited to a total time of five 
minutes (unless otherwise indicated). Speakers must also submit 
their comments in writing for inclusion in the meeting's summary 
report. To assure adequate time is scheduled for public comments, 
individuals or groups planning to make an oral presentation should, 
when possible, notify the contact person below at least one week 
prior to the meeting date.
    Written Comments: For individuals or groups unable to attend the 
meeting, CLIAC accepts written comments until the date of the 
meeting (unless otherwise stated). However, the comments should be 
received at least one week prior to the meeting date so that the 
comments may be made available to the committee for their 
consideration and public distribution. Written comments, one hard 
copy with original signature, should be provided to the contact 
person below. Written comments will be included in the meeting's 
summary report.
    Contact Person for Additional Information: Devery Howerton, 
Acting Chief, Laboratory Practice Standards Branch, Division Public 
Health Partnerships--Laboratory Systems, National Center for Health 
Marketing, Coordinating Center for Health Information and Service, 
CDC, 1600 Clifton Road, NE., Mailstop G-23, Atlanta, Georgia 30333; 
telephone (404) 718-1016; fax (404) 718-1080; or via e-mail at 
DHowerton@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining 
to announcements of meetings and other committee management 
activities, for CDC and the Agency for Toxic Substances and Disease 
Registry.

    Dated: January 12, 2007.
Edward Schultz,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
 [FR Doc. E7-720 Filed 1-18-07; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.